OQROGet OQRO Pro
Insider trade

Arrowhead Pharmaceuticals (ARWR)Chief Medical Officer sold ~$932K

James C Hamilton, Chief Medical Officer at Arrowhead Pharmaceuticals, sold ~$932K of Arrowhead Pharmaceuticals shares.

~$932K
Approx. value · 15K sh @ $63.01
187K
Holds after · shares reported
Traded
Jan 5, 2026
Filed
Jan 6, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Nov 25, 2025Company filing · Form 8-K · ResultsReported its results
  2. Nov 28, 2025InsiderDirector sold ~$493K of ARWR shares in the open market
  3. Dec 5, 2025InsiderDirector sold ~$992K of ARWR shares in the open market
  4. Dec 15, 2025Insider · 1 personInsiders: 3 sales (~$9.0M)
  5. Dec 16, 2025Insider · 1 personInsiders: 9 sales (~$3.4M)
  6. Dec 17, 2025Insider · 1 personInsiders: 4 sales (~$5.4M)
  7. Dec 19, 2025Insider · 4 peopleInsiders: 12 sales (~$2.8M)
  8. Dec 22, 2025Insider · 1 personInsiders: 2 sales (~$861K)
  9. Dec 26, 2025InsiderDirector sold ~$527K of ARWR shares in the open market
  10. Dec 29, 2025Insider · 1 personInsiders: 2 sales (~$3.6M)
  11. Jan 2, 2026Insider · 1 personInsiders: 2 sales (~$872K)
  12. Jan 5, 2026 · this disclosureInsiderOfficer sold ~$932K of ARWR shares in the open market

What came next

  1. Jan 5, 2026Insider · 2 peopleInsiders: 18 sales (~$4.7M)
  2. Jan 7, 2026Company filing · Form 8-K · Material agreement, Other newsSigned an important agreement, and reported other company news
  3. Jan 12, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
  4. Feb 5, 2026Company filing · Form 8-K · ResultsReported its results
  5. Mar 5, 2026InsiderOfficer sold ~$642K of ARWR shares in the open market
  6. Apr 22, 2026Insider · 1 personInsiders: 3 sales (~$934K)
  7. Apr 23, 2026InsiderOfficer sold ~$750K of ARWR shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Arrowhead Pharmaceuticals

For Arrowhead Pharmaceuticals, OQRO holds 2 insider filings (SEC Form 4 or Form 144) and 9 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ARWR page.

Other recent filings by James C Hamilton, Chief Medical Officer

The full history of James C Hamilton, Chief Medical Officer is on the profile page.

How this filing works

Other disclosures at Arrowhead Pharmaceuticals

Everything OQRO holds on this company is on its ARWR page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data